Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

14.6K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.6K
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

5.3K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.3K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

615
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
615
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

189
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
189
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Downregulation of EPAS1 and EGLN1 mRNA Expression Associated With High-Altitude Adaptive Genetic Variants in Sherpa Highlanders.

Annals of human genetics·2026
Same author

Community-Based Micro-Elimination of Hepatitis C Virus in a Defined Rural Cohort: Outcomes From the Nagawa Project.

Hepatology research : the official journal of the Japan Society of Hepatology·2025
Same author

Genetic Associations with the Susceptibility to High-Altitude Pulmonary Edema in the Japanese Population.

High altitude medicine & biology·2025
Same author

Identification of the Novel Allele HLA-C*04:535 by Next-Generation Sequencing.

HLA·2024
Same author

No-touch isolation technique in emergency pancreaticoduodenectomy for neoplastic hemorrhage: Two case reports and review of literature.

World journal of gastrointestinal surgery·2024
Same author

IgG4-related disease in the Japanese population: a genome-wide association study.

The Lancet. Rheumatology·2024

相关实验视频

Updated: May 5, 2026

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
07:46

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000

Published on: October 16, 2010

45.2K

内皮氧化合成酶基因多态的积极关联与高海拔肺.

Yunden Droma1, Masayuki Hanaoka, Masao Ota

  • 1Department of Medicine, Shinshu University School of Medicine, Matsumoto, Japan.

Circulation
|August 15, 2002
PubMed
概括

内皮氧化合成酶 (eNOS) 基因的遗传变异与高海拔肺 (HAPE) 有关. 这些eNOS基因多态可能作为HAPE易感性的指标.

更多相关视频

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
10:20

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice

Published on: January 16, 2013

25.2K
En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries
08:58

En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries

Published on: February 25, 2016

9.2K

相关实验视频

Last Updated: May 5, 2026

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
07:46

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000

Published on: October 16, 2010

45.2K
Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
10:20

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice

Published on: January 16, 2013

25.2K
En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries
08:58

En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries

Published on: February 25, 2016

9.2K

科学领域:

  • 遗传学 是一个遗传学.
  • 生理学 生理学 生理学
  • 高度医学 高度医学

背景情况:

  • 高海拔肺 (HAPE) 与肺部氧化 (NO) 合成受损有关.
  • 内皮氧化合成酶 (eNOS) 对于NO的产生至关重要,其基因已知多态.
  • 一些eNOS基因变异与血管疾病有关.

研究的目的:

  • 调查eNOS基因多态化与对HAPE敏感性之间的关联.
  • 为了确定HAPE风险的潜在遗传标记.

主要方法:

  • 在日本人口中研究了41名HAPE易感个体和51名健康的登山者.
  • 分析了两个eNOS基因多态:Glu298Asp变体和一个可变的27个基对 (bp) 串联重复的数量.
  • 使用聚合酶连锁反应 (PCR) 和限制片段长度多态化 (RFLP) 技术.

主要成果:

  • 与对照组 (9.8%) 相比,Glu298Asp变体的Asp等位基因频率在HAPE敏感受试者 (25.6%) 中显著更高.
  • 27-bp VNTR 的 eNOS4a 基因频率在 HAPE 敏感受试者 (23.2%) 中也明显高于对照组 (6.9%).
  • 在HAPE敏感受试者 (26.8%) 和对照者 (0%) 之间,两种风险等位基因的同时发生中观察到显著差异.

结论:

  • 两种研究的eNOS基因多态都与HAPE易感性有显著的关联.
  • 一种遗传倾向可能导致HAPE中肺部NO合成受损.
  • 这些eNOS多态可能作为预测HAPE风险的有价值的遗传标记.